TNFRSF17 and plasma cell myeloma: Anti-BCMA CAR-T cell therapy became the first cellular immunotherapy approved by the U.S. Food and Drug Administration (FDA) in 2021 for the treatment of multiple myeloma, achieving unprecedented clinical efficacy (19, 20).